Pfizer’s troubles may finally be coming to a head. Meanwhile, Hims & Hers is joining S&P SmallCap 600.

Was this article helpful?
YesNo

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Close Search Window